The Phosphodiesterase 3 Inhibitor Cilostazol as an Adjunct to Conventional Therapy in Patients With Osteoarthritis
Condition(s):OsteoarthritisLast Updated:February 1, 2024Active, not recruiting
Hide Studies Not Open or Pending
Condition(s):OsteoarthritisLast Updated:February 1, 2024Active, not recruiting
Condition(s):Diabetic Cardiomyopathy; Diabetes Mellitus Type 2Last Updated:July 10, 2019Completed
Condition(s):Erectile Dysfunction; CoronaropathyLast Updated:July 16, 2015Withdrawn
Condition(s):Improve Endothelial Function and Decrease Vascular StenosisLast Updated:August 12, 2019Completed
Condition(s):Pulmonary Hypertension; Chronic Obstructive Pulmonary DiseaseLast Updated:December 13, 2023Not yet recruiting
Condition(s):Cushing’s Syndrome CardiomyopathyLast Updated:May 16, 2023Completed
Condition(s):Acromegaly CardiomyopathyLast Updated:May 12, 2023Completed
Condition(s):Pulmonary Arterial HypertensionLast Updated:June 26, 2008Unknown status
Condition(s):Huntington DiseaseLast Updated:June 20, 2017Completed
Condition(s):Diabetes Mellitus, Type 2Last Updated:February 11, 2020Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.